Sesquient is a drug owned by Lupin Inc. It is protected by 5 US drug patents filed in 2021 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 27, 2033. Details of Sesquient's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(6 years from now) | Active |
| US9750822 | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(2 years from now) | Active |
| US9200088 | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(2 years from now) | Active |
| US8410077 | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(2 years from now) | Active |
| US7635773 | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(2 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Sesquient's patents.
Latest Legal Activities on Sesquient's Patents
Given below is the list of recent legal activities going on the following patents of Sesquient.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Feb, 2025 | US9750822 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Sep, 2024 | US8410077 |
| Application ready for PDX access by participating foreign offices | 29 May, 2024 | US8410077 |
| Application ready for PDX access by participating foreign offices | 24 May, 2024 | US7635773 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Apr, 2024 | US9493582 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 May, 2023 | US9200088 |
| Correspondence Address Change | 04 Dec, 2022 | US9200088 |
| Correspondence Address Change | 04 Dec, 2022 | US9493582 |
| Correspondence Address Change | 04 Dec, 2022 | US8410077 |
| Correspondence Address Change | 04 Dec, 2022 | US7635773 |
US patents provide insights into the exclusivity only within the United States, but
Sesquient is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Sesquient's family patents as well as insights into
ongoing legal events
on those patents.
Sesquient's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Sesquient's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 27, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Sesquient Generic API suppliers:
Fosphenytoin Sodium is the generic name for the brand Sesquient. 12 different companies have already filed for the generic of Sesquient, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Sesquient's generic
About Sesquient
Sesquient is a drug owned by Lupin Inc. Sesquient uses Fosphenytoin Sodium as an active ingredient. Sesquient was launched by Lupin in 2020.
Approval Date:
Sesquient was approved by FDA for market use on 05 November, 2020.
Active Ingredient:
Sesquient uses Fosphenytoin Sodium as the active ingredient. Check out other Drugs and Companies using Fosphenytoin Sodium ingredient
Dosage:
Sesquient is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML) | SOLUTION | Discontinued | INTRAVENOUS |
| EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML) | SOLUTION | Discontinued | INTRAVENOUS |